Most Read Articles
12 Jun 2018
Percutaneous coronary intervention (PCI) is a safe procedure to perform on obese and morbidly obese patients, a recent study has shown.
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

3 days ago
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
4 days ago
Use of quetiapine among critically ill patients rarely leads to corrected QT (QTc) interval prolongation, reports a new study.

Noninvasive assessment of portal hypertension shows promise

Jackey Suen
24 Oct 2017
Dr Yanna Liu

Virtual hepatic venous pressure gradient (vHVPG), a novel noninvasive approach to assess portal hypertension, is shown to correlate well with the gold-standard invasive method in a recent Chinese study.

“Measurement of hepatic venous pressure gradient [HVPG] is currently the standard method to assess portal hypertension. It is measured by means of catheterization of the hepatic vein with a balloon catheter, which is invasive and expensive with a high technical requirement,” explained investigator Dr Yanna Liu of the Southern Medical University, Guangzhou, Guangdong, China. “International liver associations such as the European Association for the Study of the Liver [EASL] and the American Association for the Study of Liver Diseases [AASLD] have therefore called for alternative tests to assess portal hypertension.” [J Hepatol 2015;63:743-752; Hepatology 2017;65:310-335]

Between August 2016 and April 2017, Liu and colleagues conducted the prospective CHESS-1601 study to evaluate the performance of noninvasive vHVPG in diagnosing clinically significant portal hypertension (CSPH) in 102 patients with compensated cirrhosis. Among these patients, 81.4 percent were confirmed to have CSPH by direct HVPG measurement. [https://clinicaltrials.gov/ct2/show/NCT02842697]

Results showed that vHVPG had an area under the curve of 0.88, sensitivity of 76 percent, and specificity of 90 percent in diagnosing CSPH.

The diagnostic performance of vHVPG was also better than that of other noninvasive models such as FibroScan, HVPGCT score and measurement of portal diameter. “However, the results require further validation as the current sample size is small,” said Liu.

“Portal hypertension is frequently observed in patients with cirrhosis, and is associated with a number of life-threatening complications. CSPH, defined as HVPG ≥10 mm Hg, is the strongest predictor of liver decompensation and hepatocellular carcinoma,” she explained.

“vHVPG is a novel approach combining an individual’s anatomical structure and haemodynamic changes, which allows direct simulation of HVPG,” Liu continued. “vHVPG is determined via construction of a three-dimensional hepatic vein-portal vein model with CT angiography images, followed by measurement of portal vein velocity with doppler ultrasound.”

She also emphasized the importance of obtaining quality CT images in improving the diagnostic accuracy of vHVPG.

“In our study, many cases were excluded from analysis due to poor CT image quality,” noted Liu. “Meanwhile, the correlation between vHVPG and HVPG was found to improve further in our exploratory analysis that included patients with CT images of moderate-to-excellent quality [n=50] only. In this group of patients, 66 percent were accurately classified as having CSPH, while only 8 percent were misclassified.”

“Our results suggest that vHVPG can act as a surrogate for invasive HVPG as the two methods correlated well with each other in diagnosing CSPH in cirrhotic patients,” she concluded. “However, the diagnostic performance of vHVPG should be further validated in larger cohorts of non-CSPH cases, since most of the patients [81.4 percent] in our study had CSPH as confirmed by HVPG.”

Liu received the runner-up prize of the 2017 International Digestive Disease Forum Young Investigator’s Awards for her present work.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
12 Jun 2018
Percutaneous coronary intervention (PCI) is a safe procedure to perform on obese and morbidly obese patients, a recent study has shown.
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

3 days ago
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
4 days ago
Use of quetiapine among critically ill patients rarely leads to corrected QT (QTc) interval prolongation, reports a new study.